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Abstract
Posterior capsule opacification (PCO) is a vision impairing condition that arises in some patients following cataract surgery.
The fibrotic form of PCO is caused by myofibroblasts that may emerge in the lens years after surgery. In the chick embryo
lens, myofibroblasts are derived from Myo/Nog cells that are identified by their expression of the skeletal muscle specific
transcription factor MyoD, the bone morphogenetic protein inhibitor Noggin, and the epitope recognized by the G8
monoclonal antibody. The goal of this study was to test the hypothesis that depletion of Myo/Nog cells will prevent the
accumulation of myofibroblasts in human lens tissue. Myo/Nog cells were present in anterior, equatorial and bow regions of
the human lens, cornea and ciliary processes. In anterior lens tissue removed by capsulorhexis, Myo/Nog cells had
synthesized myofibroblast and skeletal muscle proteins, including vimentin, MyoD and sarcomeric myosin. Alpha smooth
muscle actin (a-SMA) was detected in a subpopulation of Myo/Nog cells. Areas of the capsule denuded of epithelial cells
were surrounded by Myo/Nog cells. Some of these cell free areas contained a wrinkle in the capsule. Depletion of Myo/Nog
cells eliminated cells expressing skeletal muscle proteins in 5-day cultures but did not affect cells immunoreactive for
beaded filament proteins that accumulate in differentiating lens epithelial cells. Transforming growth factor-betas 1 and 2
that mediate an epithelial-mesenchymal transition, did not induce the expression of skeletal muscle proteins in lens cells
following Myo/Nog cell depletion. This study demonstrates that Myo/Nog cells in anterior lens tissue removed from cataract
patients have undergone a partial differentiation to skeletal muscle. Myo/Nog cells appear to be the source of skeletal
muscle-like cells in explants of human lens tissue. Targeting Myo/Nog cells with the G8 antibody during cataract surgery
may reduce the incidence of PCO.
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Introduction
Posterior capsule opacification (PCO) is a vision impairing
condition that arises in some patients following cataract surgery
[1,2]. Visual acuity is compromised by the formation of Elschnig
pearls that consist of differentiating lens cells (regenerative PCO)
and the emergence of myofibroblasts that migrate onto the lens
capsule and deposit extracellular matrix (fibrotic PCO) [3]. The
fibrotic form of PCO has been attributed to lens epithelial cells
that undergo an epithelial to mesenchymal transition (EMT) and a
transdifferentiation to myofibroblasts [2,4]. Several families of
molecules have been implicated in the emergence of myofibro-
blasts in lens tissue [43], including transforming growth factor beta
(TGF-b) that induces an epithelial to mesenchymal transition
(EMT), cell migration, synthesis of alpha smooth muscle actin (a-
SMA), contraction and production of extracellular matrix in
anterior and posterior lens tissue [4–18]. Contractions of
myofibroblasts produce folds and wrinkles in the thick basement
membrane surrounding the lens called the capsule [19].
Myofibroblasts in the chick embryo lens originate from Myo/
Nog cells that are incorporated into the eye during early stages of
development [20–22]. Myo/Nog cells, which exist at low
frequency in many tissues, are identified by their expression of
mRNA for the skeletal muscle specific transcription factor MyoD,
the bone morphogenetic protein (BMP) inhibitor Noggin and the
cell surface molecule recognized by the G8 monoclonal antibody
(mAb) [20,21,23–27]. Expression of MyoD is the hallmark of
Myo/Nog cells’ commitment to the skeletal muscle lineage, while
their release of Noggin is critical for modulating BMP signaling,
morphogenesis and differentiation [20,21,26,28]. Depletion of
Myo/Nog cells in the blastocyst results in severe malformations of
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the body wall, central nervous system and the eyes due to de-
regulated BMP signaling [20,21,26].
In addition to their role as the primary producer of Noggin,
Myo/Nog cells react to a perturbation in homeostasis in multiple
tissues [22,26,27]. The propensity of Myo/Nog cells to respond to
wounding reflects, in part, their innate capacity for migration and
expression of muscle proteins [20–22,24,25,29]. When removed
from embryonic and fetal tissues and cultured in serum-free
medium, they translate MyoD mRNA and undergo terminal
skeletal muscle differentiation [24,25,28,29]. In vivo, Myo/Nog
cells do not appear to translate MyoD mRNA or synthesize
sarcomeric proteins under homeostatic conditions [21,25,30].
However, when activated by apoptotic cells, epidermal abrasion,
tumorigenesis, or incisions in embryonic lens tissue, Myo/Nog
cells rapidly increase in number and migrate to the wound
[22,26,27].
The goals of this study were to determine whether the human
lens contains Myo/Nog cells and characterize their behavior in
anterior lens tissue removed by capsulorhexis during cataract
surgery. The effect of Myo/Nog cell depletion on the accumula-
tion of myofibroblasts in anterior lens tissue was tested in vitro.
Materials and Methods
Human Anterior Segments
Human anterior segments from three donors were obtained
through the National Disease Research Interchange (Philadelphia,
PA, USA). Lens sections from an additional three donors were
acquired from Excalibur Pathology, Inc. (Oklahoma City, OK,
USA). The age of the donors ranged from 52 to 96 years old. Five
eyes were procured 3–8 hours postmortem. The sixth eye was
procured 13 hours postmortem. Eyes were immediately placed in
fixative and shipped the same day. Lenses from one donor were
fixed in 4% paraformaldehyde for approximately 24 hours, cut in
quarters and embedded in OCT compound for cryosectioning.
Lenses from the other five donors were fixed in a modified
Davidson’s fixative containing 14% ethyl alcohol, 14% formalin
and 6.25% glacial acetic acid (Excalibur Pathology, Inc., USA)
and embedded in paraffin. This fixation method produced
preservation of lens morphology superior to that of paraformal-
dehyde. Tissue was sectioned at 10 mm. Some sections were
stained with Hematoxylin 7211 and Eosin-Y (Richard-Allan
Scientific, Kalamazoo, MI, USA).
Human Anterior Lens Tissue
Anterior lens tissue was removed by capsulorhexis from 283
patients during cataract surgery. The patients ranged from 55 to
91 years old. Approximately 2/3 of the patients were female. The
most common cataract subtype was nuclear sclerosis, which in the
majority of cases, was accompanied by cortical and less commonly,
posterior subcapsular cataracts. The tissue was fixed in 2%
paraformaldehyde within 10 minutes of its removal from 66
patients. Each whole piece of anterior lens tissue was cut in half
before processing for histological analysis. Other pieces of unfixed
anterior lens tissue were cultured by a modification of the methods
of Wormstone et al. [31] and Ishizaki et al. [32]. Four edges of the
capsule were pressed to a 35 mm tissue culture dish. Lens tissue
was cultured in serum and protein-free DMEM/F12 medium
(GIBCO/Life Technologies, Grand Island, NY, USA) at 37uC in
5% CO2 in air.
In Situ Hybridization and Immunofluorescence
Localization
Sections of the anterior segment or anterior lens tissue removed
during cataract surgery were examined for the expression of the
G8 epitope and mRNAs for MyoD and Noggin by incubating with
the G8 IgM MAb [25] and goat anti-mouse IgM m chain
antibodies conjugated with DyLight 488 (Invitrogen/Molecular
Probes, Eugene, OR, USA), followed by incubation in Cy3 labeled
3DNATM dendrimer nanoparticles (Genisphere, LLC, Hatfield,
PA, USA) [33]. The following anti-sense sequences were
conjugated to 3DNA: human MyoD1 (NM_002478.4:59-
CTGTCCGGCCTGATTTGT GGTTAAGGA-39) and mouse
Noggin (NM_008711.2:59-TCTCGTTCAGATCC
TTCTCCTTAGGGTCAAA-39) [34,35]. The sequence to mouse
Noggin was 94% homologous to human Noggin (29 out of 31
bases) [36] and showed the same co-localization pattern with the
G8 mAb in murine and human tissues [27].
Sections of the anterior segment and anterior lens tissue were
double labeled with the G8 IgM mAb to tag Myo/Nog cells, and
IgG mAbs to vimentin (AMF-17b) [37], alpha smooth muscle
actin (a-SMA) (directly conjugated with fluorescein; Sigma-
Aldrich, St. Louis, MO, USA) (markers of myofibroblasts), MyoD1
protein (NCL-MyoD1; Novocastra Labs Ltd, UK), slow sarco-
meric myosin (A4.951) [38], neonatal and adult sarcomeric myosin
heavy chain (MF30) [39], the skeletal muscle specific, T-tubule
associated 12101 antigen (12101) [40] and cardiac and skeletal
muscle troponin T (CT3) [41] (markers of striated muscle) by
previously described methods [23,25]. Double labeling was also
performed with the G8 mAb and goat polyclonal antibodies to
Noggin (AF719; R&D Systems, Minneapolis, MN, USA) and
rabbit polyclonal antibodies to filensin [42] and CP49 [43,44].
Controls for non-specific staining included the E12 IgM mAb [29],
2H3 IgG mAb to neurofilament protein [45] and a goat polyclonal
antiserum to the homeobox protein LBX1 expressed in the central
nervous system and some developing muscles [46] (Santa Cruz
Biotechnology, Dallas, TX, USA). Monoclonal antibodies to
vimentin, sarcomeric myosins, the 12101 antigen, troponin T and
neurofilament protein were obtained from the Developmental
Studies Hybridoma Bank (developed under the auspices of the
NICHD and maintained by the University of Iowa, Dept. of
Biology, Iowa City, IA, USA).
Primary antibodies were visualized with species- and subclass-
specific fluorescent secondary antibodies, including goat anti-
mouse or anti-rabbit IgG, goat anti-mouse IgM m chain and
donkey anti-goat IgG conjugated with DyLights 488 or 549
(Jackson ImmunoResearch, West Grove, PA, USA). Nuclei were
stained with Hoechst dye 33258 (Sigma-Aldrich). Labeling was
analyzed with the Nikon Eclipse E800 epifluorescence microscope
equipped with the Evolution QE Optronics video camera and
Image Pro Plus image analysis software program (Media
Cybernetics, Rockville, MD, USA), and Nikon Eclipse Ti
Confocal microscope and NIS-Elements software. Figures were
annotated and uniformly adjusted for brightness and contrast with
Adobe Photoshop 6.0.
The percentage of labeled cells in anterior lens tissue was
determined by counting the total numbers of stained and
unstained cells in 20 consecutive fields across the entire tissue.
The number of cells in 20 fields varied between 1,124 and 2,284.
The accuracy of this sampling method was determined by
comparing the percentage of labeled cells in 20 fields to the
percentage in the entire tissue. The values for each combination of
antibodies used for double labeling are the mean 6 standard
deviation of anterior lens tissue from different patients.
Myo/Nog Cells in the Human Lens
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Depletion of Myo/Nog Cells in Anterior Lens Cultures
Cultures containing anterior lens tissue were incubated in
Hanks buffered saline containing 0.1% bovine serum albumen
(Sigma-Aldrich) and the G8 mAb or baby rabbit complement
(Cedar Lane, Inc., Hornby, Ontario, Canada, USA) alone, or a
pre-mixed solution of G8 and complement 20 hours after plating
[21]. Explants were stained with a fluorescent secondary
antibodies to visualize the G8 mAb, and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) reagents (Roche
Diagnostics, Mannheim, Germany) five hours after treatment [26].
Other treated explants were incubated in culture medium for an
additional 4 days and then stained with antibodies to muscle and
beaded filament lens proteins.
Treatment of Wounded Anterior Lens Tissue with TGF-b
Whole pieces of anterior lens tissue were cut in half and pressed
to a culture dish. In some cultures, tissue was treated with the G8
mAb and complement to deplete Myo/Nog cells immediately after
plating. A scratch wound was produced by gently abrading the
epithelium with a knife by modification of the method of
Wormstone et al. [4,14]. The location of the wound was marked
at the edge of the tissue with a dissecting needle. Following
wounding, explants were incubated in one ml of DMEM/F12
medium alone or DMEM/F12 containing 10 gg/ml human
recombinant TGF-b2 (Sigma-Aldrich and R&D Systems, Inc.,
Minneapolis, MN, USA) or human recombinant TGF-b1 (Sigma-
Aldrich). Some cultures were treated simultaneously with TGF-b1
or 2b2 and 10 gg/ml human recombinant Noggin (PeproTech,
Inc., Rocky Hill, NJ, USA). Media were replenished 48 hours
later. Cultures were fixed 48 or 120 hours following the initiation
of treatment.
Statistical Analyses
The two-tailed Student’s t-test was used to compare the
percentages of cells labeled with antibodies to G8, a-SMA, MyoD,
myosin, filensin and CP49 in treated and control cultures.
Use of Human Tissue and Ethics Statement
This research followed the tenets of the Declaration of Helsinki.
Written informed consent was obtained from the subjects
following an explanation of the study. The project was approved
by the Institutional Review Board of Main Line Hospitals.
Results
Myo/Nog Cells are Present in the Anterior Segment of
the Human Eye
Tissue sections from the anterior segment of six donors were
probed for G8, MyoD mRNA and Noggin to determine whether
Myo/Nog cells are present in the human lens. None of the donors
were reported to have had a history of lens disease. In situ
hybridization was carried out with Cy3 labeled 3DNA dendrimers
that are extremely sensitive and precise reagents for localizing
mRNA in single cells in fresh and sectioned tissue [20,21,23,25–
27,33]. Double labeling with the G8 mAb and dendrimers to
MyoD mRNA or an antibody to Noggin revealed the presence of
Figure 1. Distribution of Myo/Nog cells in the human anterior segment. Tissue sections through the anterior segment were stained with
H&E (A) or double labeled with G8 and dendrimers to MyoD mRNA (MyoD m) or an antibody to Noggin (NOG) (B–P). The primary antibodies and
colors of the fluorescent dendrimers and secondary antibodies are indicated in each photograph. Photographs are the merged images of DIC and
fluorescence. Overlap of green and red appears yellow in merged images. Myo/Nog cells labeled for G8, MyoD mRNA and Noggin protein were
present in the anterior (E–J), equatorial (K–M) and bow regions (N–P) of the lens, corneal epithelium (B), corneal stroma (C) and ciliary processes (D).
AL = anterior lens, EL = equatorial lens, BR =bow region of the lens shown in the inset in A, CP= ciliary process, CE= corneal epithelium, S = corneal
stroma. Bar = 135 mm in A and 9 mm in B–I.
doi:10.1371/journal.pone.0095262.g001
Myo/Nog Cells in the Human Lens
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small numbers of Myo/Nog cells in the lens, epithelial and stromal
layers of the cornea, and ciliary processes (Figure 1). Each 10 mm
section of the whole lens contained an average of 464 (n= 60)
Myo/Nog cells among the lens epithelial cells. Of the total cells in
the lens labeled with the G8 mAb, 28%, 40% and 31% were
present in the anterior, equatorial and bow regions, respectively.
Single or clusters of Myo/Nog cells were found in each of these
regions, although they were not visible in all three areas in every
section (Figure 1E–P). Only one Myo/Nog cell was found between
the cortical fibers. These results are consistent with our findings in
the chick embryo [20] and adult mice and rabbits (unpublished
data) in which the eyes were removed and fixed immediately upon
death.
Myo/Nog Cells in Anterior Lens Tissue Removed by
Capsulorhexis Express Markers of Myofibroblasts and
Skeletal Muscle Cells
Anterior lens tissue, which is more readily available than whole
lenses and can be obtained within minutes of surgery, was used to
explore the properties of Myo/Nog cells in the human lens. Every
piece of anterior lens tissue that was fixed within 10 minutes of
capsulorhexis contained a small population of cells labeled with
the G8 mAb (3% 62, number of patients (n = 66) (Figure 2).
MyoD mRNA was detected in practically all G8+ cells (98% 62,
n = 4) (Figure 2A–C), and only a few MyoD mRNA+ cells lacked
staining for G8 (4% 64, n= 4). Most Myo/Nog cells had
translated MyoD mRNA into protein (Table 1; Figure 2D–F).
Noggin was localized in 99% of the G8+ cells (Table 1; Figure 2G–
I).
Single or small clusters of 2–4 Myo/Nog cells appeared to be
randomly distributed among the lens epithelial cells (Fig. 2A–I).
Approximately 35% of the anterior lenses contained clusters
ranging from 4–40 Myo/Nog cells lying on the apical surface of
the epithelial cells (Figure 2J–L). The presence of apical clusters
did not appear to correlate with the age (55–89 years), cataract
subtype (nuclear sclerosis with or without cortical and/or posterior
subcapsular) or grade (2–4) of the donor. Most lenses lacked G8+
cells along the incision created during the initiation of capsulor-
hexis (Figure 2M); however, in 15% of the specimens, G8+ cells
were intermittently aligned along the incisional edge (Figure 2O).
By contrast, all cells along the entire periphery of the tissue were
intensely labeled with an antibody to the intermediate filament
protein vimentin, (Figure 2N and P). Less intense vimentin staining
was observed throughout the epithelium (Figure 2N and P). The
specificity of staining with the G8 and vimentin antibodies along
the edge of the tissue was demonstrated by the absence of
fluorescence when the tissue was incubated with the E12 IgM
mAb, 2H3 IgG mAb and their respective secondary antibodies
(Figure 2R and S) or secondary antibodies alone (not shown).
Thus, in some samples, Myo/Nog cells appear at the incisional
border of the tissue.
The state of differentiation of Myo/Nog cells in the lens was
determined by screening for markers of myofibroblasts and skeletal
muscle cells. Low numbers of cells throughout the lens tissue were
labeled with antibodies to muscle proteins (Table 1; Figure 3).
Whereas only a small percentage of the G8+ cells contained
detectable levels of a-SMA, most or all G8+ cells had synthesized
MyoD, sarcomeric myosins, the skeletal muscle specific, T-tubule
associated 12101 molecule and troponin T (Table 1), indicating
that Myo/Nog cells synthesize proteins characteristic of skeletal
muscle.
Approximately 76% of the anterior lenses contained small areas
in which the epithelial cells had been denuded from the capsule.
These areas were distant from the edges of the tissue pressed
against the tissue culture dish. A wrinkle was present in the capsule
in at least one of these cell free areas in approximately one third of
the samples (Figure 3I, L, U and V). Myo/Nog cells had formed a
thickened rim around these cell free areas (Figure 3A–V). Most of
Figure 2. Distribution of Myo/Nog cells in human anterior lens tissue removed during cataract surgery. A low magnification DIC image
of anterior lens tissue fixed after capsulorhexis is shown in the inset in A. Tissue was double labeled with the G8 mAb and dendrimers to MyoD mRNA
(MyoD m) or antibodies to MyoD protein (MyoD p), Noggin (NOG) or vimentin (VM). The primary antibodies and colors of the fluorescent dendrimers
and secondary antibodies are indicated in each photograph. Unmerged images precede the merged images shown in C, F, I, L and Q. Overlap of
green and red appears yellow in merged images. Nuclei were stained with Hoechst dye (HCT) (blue). Anterior lens tissue contained single, small
groups or large clusters of Myo/Nog cells throughout the epithelium (A–L). Photographs in J-L illustrate a cluster of G8+ cells lying on the apical
surface of lens epithelial cells. The underlying layer of nuclei in the same field is shown in the inset in J. G8+ cells were present along the cut edge of
some (O) but not all samples (M). Vimentin staining was most intense at the periphery of the tissue (N and P). Tissue incubated with the E12 IgM or
2H3 IgG and their respective secondary antibodies lacked fluorescence (R and S). Bar = 5 mm in the inset in A and 9 mm in the other
photomicrographs.
doi:10.1371/journal.pone.0095262.g002
Myo/Nog Cells in the Human Lens
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the G8+ cells surrounding the bare areas of capsule expressed
MyoD mRNA and stained with antibodies to MyoD protein,
Noggin, a-SMA, vimentin (not shown), sarcomeric myosin, 12101
and troponin T (Figure 3A–V). The specificity of antibody binding
in Myo/Nog cells was demonstrated by the lack of staining around
the edges of cell free areas following incubation with the E12 and
2H3 mAbs, the LBX1 goat polyclonal antiserum and their
respective secondary antibodies (Figure 3W–Y), or secondary
antibodies alone (not shown). Although Myo/Nog cells expressed
sarcomeric proteins, they did not appear striated. Some Myo/Nog
cells were present on the capsule within the cell free areas and had
extended processes towards the wrinkle (Figure 3V).
Depletion of Myo/Nog Cells in Cultures of Anterior Lens
Tissue Prevents the Accumulation of Cells Expressing
Muscle Proteins
The effect of depleting Myo/Nog cells on the accumulation of
muscle cells in explants of anterior lens tissue was determined by
lysing cells that bound the G8 mAb with complement [21]. Five
hours following treatment with G8 and complement, 99% 61 of
the G8+ cells, but only 3% 63 of the G8- cells (n = 5) were
Table 1. Myo/Nog cells in anterior lens tissue are immunoreactive for proteins found in skeletal muscle and lens tissue.
Antibody % Ab Positive % Ab Positive with G8 % G8 Positive with other Ab
MyoD 262 100 94612
Noggin 362 9961 9962
Vimentin 92610 662 100
a-SMA 161 30626 12611
Sarcomeric Myosin 461 93616 90619
12101 462 81627 90612
Troponin T 261 100 54625
Anterior lens tissue was fixed within 10 minutes of capsulorhexis and double labeled with G8 and other antibodies (Ab) and species and subclass specific fluorescent
secondary antibodies. % Ab Positive = number of fluorescent cells 4 total number of cells in 20 fields X 100. % Ab Positive with G8 = number of antibody positive cells
co-labeled with G8 4 total antibody positive cells X 100. Percent G8 Positive Cells with Other Ab =number of G8 positive cells co-labeled with the other antibody 4
total number of G8 positive cells X 100. Four cultures were scored for each pair of antibodies except G8+ Noggin (n = 9) and G8+ a-SMA (n = 10).
doi:10.1371/journal.pone.0095262.t001
Figure 3. Myo/Nog cells in human anterior lens tissue express muscle proteins. Anterior lens tissue fixed after capsulorhexis was double
labeled with the G8 mAb and dendrimers to MyoD mRNA (MyoD m) or antibodies to MyoD protein (MyoD p), Noggin (NOG), a-SMA, sarcomeric
myosin heavy chain (MYOSIN), the skeletal muscle specific 12101 antigen (12101) and troponin T (TPNT). The primary antibodies and colors of the
fluorescent dendrimers and secondary antibodies are indicated in each photograph. Overlap of green and red appears yellow in merged images.
Nuclei were stained with Hoechst dye (blue). Panels I, L, U and V are quadruple merged images of DIC and fluorescence showing wrinkles in the
capsule (arrow in I). G8+ cells co-stained for MyoD mRNA, Noggin and muscle proteins surrounded cell free areas of the capsule (A–V). Some Myo/
Nog cells had migrated onto the capsule (arrows in V). Tissue incubated with the E12 or 2H3 mAbs, or an antiserum to LBX1 and their respective
secondary antibodies, lacked fluorescence (W–Y). Bar = 9 mm.
doi:10.1371/journal.pone.0095262.g003
Myo/Nog Cells in the Human Lens
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undergoing apoptosis, as indicated by TUNEL staining
(Figure 4A). In cultures treated with the G8 mAb or complement
only, 2% 62 and 5% 68 of the G8+ and G8- cells, respectively,
were TUNEL+ (n = 6) (Figure 4B and C). This experiment
demonstrates that Myo/Nog cells are specifically targeted when
lens explants are treated with G8 and complement.
Four days following Myo/Nog cell depletion, cultures were
labeled with antibodies to G8 and muscle proteins. Treatment
with both G8 and complement eliminated G8+ cells in 12 out of
16 cultures and left only a few G8+ cells in the remaining cultures
(Table 2, Figure 4D–H). The percentage of a-SMA+ cells was
reduced approximately 6-fold following treatment with G8 and
complement (Table 2, Figure 4E) and only 1% 63 of the a-SMA+
cells were co-labeled with the G8 mAb. Complete elimination of
G8+ cells in 5-day cultures was accompanied by an absence of
MyoD+ and sarcomeric myosin+ cells (Figure 4E and F). By
contrast, ablation of Myo/Nog cells did not prevent the
accumulation of cells immunoreactive for the beaded filament
proteins filensin and CP49 that are synthesized in differentiating
lens cells (Table 2, Figure 4G and H). Control cultures treated with
G8 (Table 2, Figure 4I–M) or complement alone contained cells
with muscle and beaded filament proteins (Table 2). These
experiments demonstrate that Myo/Nog cells are not replenished
following treatment with the G8 mAb and complement, and the
depletion protocol inhibits the accumulation of myogenic cells.
TGF-b Does Not Induce Expression of Skeletal Muscle
Proteins in the Absence of Myo/Nog Cells
Anterior lens tissue depleted of Myo/Nog cells was further
challenged to produce muscle cells by creating a scratch wound in
the epithelium and incubating with TGF-b2 [4,15,47–49]. The
wound healing response varied within and between treatment
groups. Cells had partially filled in the wound within 48 hours in
two out of three untreated explants (Figure 5A). Treatment with
TGF-b2 for two days resulted in partial to complete wound closure
in four out of 7 explants (Figure 5B). Only one out of five explants
displayed partial wound healing following ablation of Myo/Nog
cells (Figure 5C). The combination of Myo/Nog cell depletion,
wounding and treatment with TGF-b2 resulted in the loss of
approximately 50–90% of the cells by 48 hours (Figure 5D). We
Figure 4. Effects of targeting Myo/Nog cells with the G8 mAb and complement in anterior lens explants. Explants of lens tissue were
incubated with the G8 mAb and complement (A, D–H), G8 only (B, I–M) or complement only (C). Five hours later, the tissue was double labeled with
the G8 mAb (green) and TUNEL reagents (red). Nuclei were stained with Hoechst dye. G8+, but not G8- cells, were TUNEL+ following treatment with
G8 and complement (A). G8+ cells were not TUNEL+ when treated with G8 or complement alone (B and C). Five days following ablation, explants
were double labeled with antibodies to G8 and MyoD, a-SMA, sarcomeric myosin heavy chain (MYOSIN), filensin and cp49. The colors of the
fluorescent secondary antibodies are indicated in each photograph. Overlap of green and red appears yellow in merged images. Ablation of Myo/
Nog cells prevented the accumulation of G8+, MyoD+ and a-SMA+ cells, but not filensin+ and cp49+ cells (D–H). Both muscle and beaded filament
proteins were detected in explants treated with the G8 mAb alone (I–M). Bar = 9 mm.
doi:10.1371/journal.pone.0095262.g004
Myo/Nog Cells in the Human Lens
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reasoned that the detrimental effect of TGF-b2 in explants lacking
Myo/Nog cells could reflect the loss of Noggin. Indeed, addition of
Noggin at the same time as TGF-b2 prevented cell loss throughout
the explant in the absence of Myo/Nog cells, and the wounds were
partially or completely filled in all five explants (Figure 5E and F).
By the fifth day after wounding, a-SMA+, MyoD+ and
sarcomeric myosin+ cells were abundant in the wounds in
untreated and TGF-b2 treated explants (Figure 6A–D). By
contrast, no MyoD+ or myosin+ cells were detected within the
wounds or throughout the tissue following depletion of Myo/Nog
cells in the presence or absence TGF-b2 and Noggin (Figure 6E–
H; Table 3). The percentages of a-SMA+ cells varied between
explants (Table 3). Five out of six explants treated with TGF-b2
had less than 8% a-SMA+ cells; however in one explant, 60%
were a-SMA+. The higher percentage of a-SMA+ cells in this
tissue did not appear to correlate with age or the type or grade of
cataract (age 70 with nuclear sclerosis (NS), grade 2 compared to
those with #8% a-SMA+ cells, ages 65–86 with NS, NS with
cortical (C) or NS with posterior subcapsular (PS) cataract, grades
2–4). The percentages of a-SMA+ cells remained consistently low
following depletion of Myo/Nog cells in the presence or absence of
TGF-b2 (Table 3).
Unlike treatment with TGF-b2, cell loss was not observed in
response to TGF-b1 following depletion of Myo/Nog cells
Table 2. Effect of depleting Myo/Nog cells on the accumulation of cells immunoreactive for muscle and beaded filament proteins
in anterior lens cultures.
G8 mAb Tx Comp Tx G8 mAb+Comp Tx
% G8+ 11613 (19) 18612 (4) 0.160.1 (16)
% a-SMA+ 22615 (4) 24614 (4) 464 (6)
% MyoD+ 565 (5) ND 0 (6)
% Myosin+ 561 (4) ND 0 (4)
% Filensin+ 1868 (4) ND 1269 (4)
% CP49+ 1265 (4) ND 24612 (4)
Anterior lens tissue was incubated with the G8 mAb or complement (Comp) alone, or G8 and complement, 20 hours after plating. Cultures were double labeled with
antibodies to G8 and a-SMA, MyoD, sarcomeric myosin, filensin or CP49 on the fifth day in culture. Values are the mean 6 standard deviation of the number of
antibody-positive cells4 total cells X 100. The number of cultures scored is indicated in parentheses. No significant differences were found between the percentages of
G8+ or a-SMA+ cells treated with either the G8 mAb or complement alone. Significant differences were found in cultures treated with either the G8 mAb or
complement alone and G8+ complement in the percentages of G8+ (0.003 and 0.0001, respectively), a-SMA+ (0.02 and 0.006, respectively), MyoD+ (0.0001) and
myosin+ cells (0.0001). No significant differences were found between the percentages of filensin+ and CP49+ cells in cultures treated with G8 or G8+ complement.
doi:10.1371/journal.pone.0095262.t002
Figure 5. Effects of Myo/Nog cell depletion and TGF-b2 on wound healing in anterior lens explants. A scratch wound was created in
explants of anterior lens tissue. Cells had populated the capsule denuded of cells within 48 hours of wounding (A). The wound was also covered with
cells following treatment with TGF-b2 (B). Few cells were present in the wound of an explant depleted of Myo/Nog cells (-M/N) (C). The combination
of wounding, depletion of Myo/Nog cells and treatment with TGF-b2 resulted in a loss of most cells from the capsule (D). Addition of Noggin (NOG)
prevented cell loss resulting from depletion of Myo/Nog cells and treatment with TGF-b2 (E) and promoted wound healing (F). Bar = 27 mm in A-C
and F, and 135 mm in D and E.
doi:10.1371/journal.pone.0095262.g005
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(Figure 6I and J). In the presence of Myo/Nog cells, no significant
differences were observed in the percentages of a-SMA+, MyoD+
or sarcomeric myosin+ cells with or without TGF-b1 or 2b2, or
between the two TGF-bs, with the exception of TGF-b1’s effect on
increasing the size of the MyoD+ population (0.04). Following
Myo/Nog cell depletion, the percentage of a-SMA+ cells was
greater in response to TGF-b1 compared to TGF-b2 and Noggin
(0.03); however, the results were highly variable (Table 3;
Figure 6G, H, K and L). Large numbers of a-SMA+ cells did
not appear to correlate with age or the type and grade of cataract
(99% a-SMA+: ages 74 and 88, NS/C, grade 2/2 and NS/C/PS,
grade 2/2/1, respectively; 22–27% a-SMA+: ages 83 and 74, NS/
C, 2/2 and NS, 3, respectively). As was the case with TGF-b2, no
MyoD+ or sarcomeric myosin+ cells were detected following
Figure 6. Effect of TGF-b on the accumulation of cells with muscle proteins following wounding and depletion of Myo/Nog cells.
Anterior lens explants were wounded and incubated in medium alone (untx) or medium containing TGF-b2 or2b1. Myo/Nog cells were ablated (abl)
in some explants prior to wounding. Cells were double labeled with antibodies to a-SMA (green) and MyoD or sarcomeric myosin (red). Nuclei were
stained with Hoechst dye. Photographs were taken of the wounded area. Explants incubated in the presence or absence of TGF-b2 or2b1 contained
a-SMA+, MyoD+ and myosin+ cells (A–D, I and J). Following depletion of Myo/Nog cells, a-SMA+ cells were less prevalent in the wounds of untreated
(E and F) and TGF-b2 treated explants (G and H) than those treated with TGF-b1 (K). No MyoD+ or myosin+ cells were observed in the wounds
following Myo/Nog cell depletion and incubation in the presence (G, H, K and L) or absence (E and F) of TGF-b2 or 2b1. Bar = 9 mm.
doi:10.1371/journal.pone.0095262.g006
Table 3. Effect of TGF-b on the accumulation of cells with muscle proteins in the presence and absence of Myo/Nog cells.
Treatment % a-SMA+ % MyoD+ % Myosin+
Wd 666 (7) 463 (4) 1169 (3)
Ab+Wd 262 (3) 0 (3) 0 (3)
Wd+TGF-b2 12621 (7) 762 (3) 563 (4)
Ab+Wd+TGF-b2+Nog 364 (4) 0 (3) 0 (4)
Wd+TGF-b1 12611 (5) 862 (4) 462 (3)
Ab+Wd+TGF-b1 62643 (4) 0 (4) 0 (4)
Ab+Wd+TGF-b1+Nog 13613 (4) 0 (4) 0 (4)
Some explants of anterior lens tissue were treated with the G8 mAb and complement to ablate (Ab) Myo/Nog cells. All explants were wounded (Wd) by scratching the
epithelium. Explants were cultured in DMEM/F12 medium alone or medium containing TGF-b2 or 2b1 with or without Noggin (Nog). Cells were double labeled with
antibodies to a-SMA and MyoD or sarcomeric myosin. Values are the mean 6 standard deviation of the number of antibody positive cells 4 total cells X 100. The
number of cultures scored is indicated in parentheses. Neither TGF-b2 nor 2b1 stimulated the accumulation of MyoD+ or myosin+ cells following Myo/Nog cell
ablation.
doi:10.1371/journal.pone.0095262.t003
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depletion of Myo/Nog cells and treatment with TGF-b1 with or
without Noggin (Figure 6K and L; Table 3). Combined, these
results demonstrate that neither form of TGF-b stimulates the
accumulation of cells expressing skeletal muscle proteins in the
absence of Myo/Nog cells.
Discussion
PCO occurs in approximately 10–20% in adults and 40–100%
in children within two years of cataract surgery [50–53]. The
incidence of PCO continues to rise three to six years post-
operatively [52]. Although PCO may be ameliorated with Yttrium
Aluminum Garnet (Nd:YAG) laser treatment, Nd:YAG:laser is not
available worldwide and some patients develop serious complica-
tions from the procedure, including corneal edema and retinal
detachment [1]. The incidence of PCO has been reduced or
delayed by improvements in surgical and drug delivery techniques
and intraocular lens composition and design [54,55]; however,
prevention of PCO remains an important goal in ophthalmology.
Fibrotic disease of the lens has been attributed to lens epithelial
cells that undergo an EMT and a transdifferentiation to
myofibroblasts [2,4]. The capacity of epithelial cells in multiple
tissues to undergo an EMT has been widely demonstrated in the
developing embryo and during the invasion and metastasis of
carcinomas [56–58]. However, multiple non-epithelial sources of
myofibroblasts have been identified within the tumor stroma,
wounds and fibrotic tissues [59–63], indicating that EMT is not
necessarily required for the appearance of muscle-like cells in
pathological environments.
We propose that a subpopulation of inherently myogenic cells
within the lens contributes to the fibrotic form of PCO. In the
embryo, these Myo/Nog cells originate in the epiblast, migrate
and are integrated into the lens and retina during early stages of
development [20,21]. The origin of MyoD+/Noggin+/G8+ cells
in the human lens is unknown, but their molecular signature and
behaviors resemble those of Myo/Nog cells in avian, rodent and
other human tissues [20–22,27]. The premise that Myo/Nog cells
in the human lens are a separate population from the lens fiber
lineage is supported by the fact that G8+ cells specifically
synthesize skeletal muscle proteins and their depletion prevents
the emergence of skeletal muscle-like cells over time in culture
without affecting the accumulation of cells immunoreactive for
beaded filament proteins. These data are consistent with our
previous findings demonstrating that Myo/Nog cells are a distinct
subpopulation within the embryonic lens and they retain their
myogenic properties in a variety of non-muscle tissues
[20,21,25,28].
The behavioral repertoire of Myo/Nog cells may be viewed as a
continuum that is regulated by the environment. The parent
Myo/Nog cell modulates the activities of BMPs in a variety of
tissues and has repressed myogenic potential, as evidenced by the
expression of MyoD mRNA without detectable levels of transla-
tion under homeostatic conditions [20,21,26,28]. When isolated
from the embryo and cultured in serum free medium, Myo/Nog
cells translate MyoD mRNA, differentiate, fuse and assemble
sarcomeres [24,25,29]. In response to a perturbation of homeo-
stasis in vivo, Myo/Nog cells expand in number and rapidly appear
at the wound [22,26,27]. Both Myo/Nog cells in the cataractous
human lens (present study) and myofibroblasts [64–67] express
multiple skeletal muscle genes, including MyoD, but they do not
fuse or assemble sarcomeres [62,64–67]. Even a-SMA, a
commonly used marker for myofibroblasts and smooth muscle,
is also expressed in embryonic and neonatal skeletal muscle [68].
Therefore, the development of Myo/Nog cells into myofibroblasts
in response to injury appears to represent a partial, yet functional
fulfillment of their myogenic potential.
The innate capacity of Myo/Nog cells to synthesize contractile
proteins and their distribution around discontinuities in the
epithelium are consistent with the interpretation that they were
responsible for producing wrinkles in the capsule. Holes in the
epithelium, called intercellular vesicles, were observed in sections
of cataractous lenses [69,70]. Gaps between human anterior
epithelial cells can be produced from contractions induced by
saline, acetylcholine or mechanical stimulation [71]. Importantly,
expression of a-SMA is not required for contraction in lens
cultures [49], suggesting that the expression of other muscle
proteins, such as those synthesized by Myo/Nog cells, may be
important mediators of capsular wrinkling.
While Myo/Nog cells in the human lens may have surrounded
areas of the capsule denuded of epithelial cells and extended
lamellipodia towards the wrinkle prior to surgery, their less
common appearance at the cut edge of the tissue within 10
minutes of capsulorhexis may reflect a rapid migration to the
wound, as observed in the chick embryo lens and murine skin
[22,27]. Another relatively rare phenomenon observed in this
study was the appearance of Myo/Nog cells on the apical surface
of lens epithelial cells. To our knowledge, cells interposed between
the anterior epithelium and fibers in vivo have not been reported;
however, in chick embryo capsular bag cultures, Myo/Nog cells
do migrate on the surface of epithelial cells [22]. The occasional
accumulation of Myo/Nog cells on the apical surface of lens
epithelial cells and at the edge of the tissue may result from
mechanical stretching that occurred during capsulorhexis and/or
wounding of the epithelial sheet.
Depleting Myo/Nog cells in lens explant cultures significantly
reduced the a-SMA+ population and eliminated MyoD+ and
sarcomeric myosin+ cells. Addition of TGF-b1 or 2b2 had
variable effects on the accumulation of a-SMA+ cells that did not
correlate with the type or grade of the cataract, and therefore, may
reflect subtle differences in the tissue or its handling. Previous
reports have documented a more consistent elevation of a-SMA in
human lens cells by TGF-b [4,14,15,49]. Differences between the
results reported herein and previous studies may be attributed to
the source of the tissue (anterior lens tissue, posterior capsular bag
model or a lens epithelial cell line), method of measuring a-SMA
(Western blot, RT-PCR or qualitative versus quantitative immu-
nofluorescence microscopy), and length of exposure to TGF-bs (2–
28 days).
While the effects of TGF-bs on a-SMA expression were
variable, neither TGF-b1 nor 2b2 stimulated the emergence of
MyoD+ or sarcomeric myosin+ cells following depletion of Myo/
Nog cells. These experiments further support the conclusion that
Myo/Nog cells are a primary source of contractile myofibroblasts
that express multiple skeletal muscle proteins following injury to
lens tissue. Furthermore, Myo/Nog cells may modulate potential
interactions between the BMP and TGF-b signaling pathways in
the human lens, as evidenced by the ability of exogenous Noggin
to prevent cell loss in response to TGF-b2.
This study provides proof of concept that Myo/Nog cells are
potential targets in the human lens for reducing the fibrotic form
of PCO and capsular wrinkling. Testing the safety and efficacy of
Myo/Nog cell depletion in a preclinical model of cataract surgery
may further establish the feasibility of immunotherapy to prevent
secondary cataract formation. Depletion of Myo/Nog cells may
also prove therapeutic in other tissues prone to fibrosis.
Myo/Nog Cells in the Human Lens
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